Rheumatoid arthritis

Clinical application of synovial biopsy in noninflammatory and persistent inflammatory refractory rheumatoid arthritis

Ann Rheum DisPublished Prospective cohort study

Main finding · Synovial histopathologyResult — go to the resultRelative risk 1.6 95% CI 1.2–2.9

Authors' conclusion

Our findings demonstrate distinct synovial and clinical phenotypes in refractory RA. Although PIRRA appears driven by active synovial inflammation and immune cell infiltration, NIRRA involves predominantly pauci-immune/fibroid histology with significant noninflammatory contributors to disease burden.

Study context

Population
Adults with established rheumatoid arthritis (RA) and active disease (CDAI >10), two academic rheumatology centres
Participants
93 biopsied patients
Exposure
PIRRA vs noninflammatory refractory RA (NIRRA) vs nonrefractory RA (NORRA)
Outcome
Synovial pathology: Krenn Synovitis Score and immunohistochemistry pathotype (lympho-myeloid, diffuse-myeloid, pauci-immune/fibroid)
Methodological detailsobservational, two academic rheumatology centres, ultrasound-guided synovial biopsy
  • Observational
  • Two academic rheumatology centres
  • Ultrasound-guided synovial biopsy

Main finding

Synovial histopathology

Relative risk

1.6

95% CI 1.2–2.9

P = 0.006

Events by group

NIRRA

47.6%

21/43 events

NIRRAvs PIRRA
RR 1.6 (95% CI 1.2–2.9); P = 0.006

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeP value
PainNIRRA vs PIRRA · significantly greater pain in NIRRA · similar overall disease activity scoresP = 0.005
Opioid useNIRRA vs PIRRA · higher opioid use in NIRRAP = 0.015

Health-related quality of life

Worse in NIRRA than PIRRA or NORRA

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Clinical application of synovial biopsy in noninflammatory and persistent inflammatory refractory rheumatoid arthritis. Ann Rheum Dis. Published 22 August 2025. doi:10.1016/j.ard.2025.07.023

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.